WO2011070172A1 - Agents anti-inflammatoires dirigés contre les épitopes citrullinés - Google Patents

Agents anti-inflammatoires dirigés contre les épitopes citrullinés Download PDF

Info

Publication number
WO2011070172A1
WO2011070172A1 PCT/EP2010/069431 EP2010069431W WO2011070172A1 WO 2011070172 A1 WO2011070172 A1 WO 2011070172A1 EP 2010069431 W EP2010069431 W EP 2010069431W WO 2011070172 A1 WO2011070172 A1 WO 2011070172A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
antibodies
antibody
human
group
Prior art date
Application number
PCT/EP2010/069431
Other languages
English (en)
Inventor
Jozef Maria Hendrik Raats
Renato Gerardus Silvano Chirivi
Original Assignee
Modiquest B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2010329842A priority Critical patent/AU2010329842B2/en
Priority to EP10788080.9A priority patent/EP2509999B1/fr
Priority to CA2783691A priority patent/CA2783691C/fr
Priority to KR1020127017692A priority patent/KR101786136B1/ko
Priority to ES10788080.9T priority patent/ES2587083T3/es
Priority to US15/449,623 priority patent/USRE46990E1/en
Application filed by Modiquest B.V. filed Critical Modiquest B.V.
Priority to US13/514,923 priority patent/US9109019B2/en
Priority to JP2012542572A priority patent/JP5980683B2/ja
Publication of WO2011070172A1 publication Critical patent/WO2011070172A1/fr
Priority to US14/742,990 priority patent/US10233236B2/en
Priority to US16/227,047 priority patent/US20190119368A1/en
Priority to US16/984,515 priority patent/US20210087260A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Abstract

La présente invention se situe dans le domaine du traitement prophylactique ou thérapeutique de l'inflammation chez l'humain et l'animal et concerne des compositions pharmaceutiques et des méthodes de traitement prophylactique ou thérapeutique de divers états inflammatoires. La présente invention concerne en particulier des compositions et des méthodes de traitement prophylactique ou thérapeutique d'états inflammatoires, tels que les maladies inflammatoires faisant intervenir la citrulline. La présente invention concerne des molécules à liaison spécifique dirigées contre les épitopes contenant de la citrulline pour l'emploi dans le traitement prophylactique et thérapeutique d'états inflammatoires.
PCT/EP2010/069431 2009-12-10 2010-12-10 Agents anti-inflammatoires dirigés contre les épitopes citrullinés WO2011070172A1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP10788080.9A EP2509999B1 (fr) 2009-12-10 2010-12-10 Agents anti-inflammatoires dirigés vers les épitopes citrullinés
CA2783691A CA2783691C (fr) 2009-12-10 2010-12-10 Agents anti-inflammatoires diriges contre les epitopes citrullines
KR1020127017692A KR101786136B1 (ko) 2009-12-10 2010-12-10 시트룰린화된 에피토프에 대해 유도된 소염제
ES10788080.9T ES2587083T3 (es) 2009-12-10 2010-12-10 Agentes anti-inflamatorios dirigidos contra epítopos citrulinados
US15/449,623 USRE46990E1 (en) 2009-12-10 2010-12-10 Anti-inflammatory agents
AU2010329842A AU2010329842B2 (en) 2009-12-10 2010-12-10 Anti-inflammatory agents directed against citrullinated epitopes
US13/514,923 US9109019B2 (en) 2009-12-10 2010-12-10 Anti-inflammatory agents
JP2012542572A JP5980683B2 (ja) 2009-12-10 2010-12-10 シトルリン化エピトープに対する抗炎症剤
US14/742,990 US10233236B2 (en) 2009-12-10 2015-06-18 Method of treating or preventing rheumatoid arthritis
US16/227,047 US20190119368A1 (en) 2009-12-10 2018-12-20 Method of Treating or Preventing Rheumatoid Arthritis
US16/984,515 US20210087260A1 (en) 2009-12-10 2020-08-04 Method of Treating or Preventing Rheumatoid Arthritis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09178658A EP2332987A1 (fr) 2009-12-10 2009-12-10 Agents anti-inflammatoires dirigés vers les épitopes citrullinés
EP09178658.2 2009-12-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/514,923 A-371-Of-International US9109019B2 (en) 2009-12-10 2010-12-10 Anti-inflammatory agents
US14/742,990 Division US10233236B2 (en) 2009-12-10 2015-06-18 Method of treating or preventing rheumatoid arthritis

Publications (1)

Publication Number Publication Date
WO2011070172A1 true WO2011070172A1 (fr) 2011-06-16

Family

ID=42061173

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/069431 WO2011070172A1 (fr) 2009-12-10 2010-12-10 Agents anti-inflammatoires dirigés contre les épitopes citrullinés

Country Status (8)

Country Link
US (5) USRE46990E1 (fr)
EP (3) EP2332987A1 (fr)
JP (1) JP5980683B2 (fr)
KR (1) KR101786136B1 (fr)
AU (1) AU2010329842B2 (fr)
CA (2) CA2783691C (fr)
ES (1) ES2587083T3 (fr)
WO (1) WO2011070172A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109185A1 (fr) * 2012-01-19 2013-07-25 Vilara Ab Nouveaux anticorps
WO2015116896A1 (fr) * 2014-01-31 2015-08-06 The General Hospital Corporation Traitement de la septicémie et du choc septique
US9109019B2 (en) 2009-12-10 2015-08-18 Modiquest B.V. Anti-inflammatory agents
WO2016092082A1 (fr) * 2014-12-11 2016-06-16 Modiquest B.V. Méthode de traitement de la fibrose pulmonaire idiopathique
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
WO2020038963A1 (fr) 2018-08-21 2020-02-27 Modiquest B.V. Anticorps se liant à l'histone citrullinée 2a et/ou 4
EP4085973A1 (fr) 2021-05-04 2022-11-09 Citryll B.V. Inhibition de pièges extracellulaires éosinophiles
WO2022233931A1 (fr) 2021-05-04 2022-11-10 Citryll B.V. Inhibition de la formation de pièges à éosinophiles
US11866512B2 (en) * 2017-11-22 2024-01-09 Vacara Ab Antibodies to citrullinated proteins

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3007411B1 (fr) * 2013-06-21 2015-07-03 Agronomique Inst Nat Rech Anticorps monocatenaire a chaine lourde de camelide dirige contre la chromatine et utilisations
GB202103164D0 (en) * 2021-03-08 2021-04-21 Adiga Life Sciences Inc Therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022503A2 (fr) 1996-11-15 1998-05-28 Stichting Scheikundig Onderzoek Nederland Peptide derive d'un antigene reconnu par des auto-anticorps provenant de patients souffrant de polyarthrite rhumatoide, anticorps dirige contre ce peptide, antigene combinatoire et procede de detection d'anticorps auto-immuns
WO2004078098A2 (fr) 2003-03-07 2004-09-16 London Health Sciences Centre Research Inc. Peptides associes a des molecules hla-dr mhc de classe ii impliquees dans des maladies auto-immunes
WO2009147201A2 (fr) * 2008-06-04 2009-12-10 Modiquest B.V. Agents anti-inflammatoires

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4777785B2 (ja) * 2006-01-31 2011-09-21 独立行政法人科学技術振興機構 ケモカインレセプターｃｃｒ５のｎ末端領域に対する抗体酵素
EP2332987A1 (fr) 2009-12-10 2011-06-15 ModiQuest B.V. Agents anti-inflammatoires dirigés vers les épitopes citrullinés

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022503A2 (fr) 1996-11-15 1998-05-28 Stichting Scheikundig Onderzoek Nederland Peptide derive d'un antigene reconnu par des auto-anticorps provenant de patients souffrant de polyarthrite rhumatoide, anticorps dirige contre ce peptide, antigene combinatoire et procede de detection d'anticorps auto-immuns
WO2004078098A2 (fr) 2003-03-07 2004-09-16 London Health Sciences Centre Research Inc. Peptides associes a des molecules hla-dr mhc de classe ii impliquees dans des maladies auto-immunes
WO2009147201A2 (fr) * 2008-06-04 2009-12-10 Modiquest B.V. Agents anti-inflammatoires

Non-Patent Citations (34)

* Cited by examiner, † Cited by third party
Title
ARTHRITIS AND RHEUMATISM, vol. 39, no. 5, 1996, pages 713 - 722
BENIAC ET AL., J STRUCT BIOL, vol. 129, 2000, pages 80 - 95
BOGGS ET AL., J NEUROSCI RES, vol. 57, 1999, pages 529 - 535
CAO ET AL., BIOCHEMISTRY, vol. 38, 1999, pages 6157 - 6163
CHAVANAS ET AL., GENE, vol. 330, 2004, pages 19 - 27
ERNST WAGNER ET AL: "Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis", RHEUMATOLOGY INTERNATIONAL ; CLINICAL AND EXPERIMENTAL INVESTIGATIONS, SPRINGER, BERLIN, DE LNKD- DOI:10.1007/S00296-009-0854-2, vol. 29, no. 11, 28 January 2009 (2009-01-28), pages 1315 - 1321, XP019738721, ISSN: 1437-160X *
HILL ET AL., J EXP MED, vol. 205, 2008, pages 967 - 979
ISHIDA-YAMAMOTO ET AL., J INVEST DERMATOL, vol. 114, 2000, pages 701 - 705
KUHN ET AL., J. CLIN. INVEST, vol. 116, 2006, pages 961 - 871
KUNA ANDREA TESIJA ET AL: "Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis.", CLINICAL CHEMISTRY AND LABORATORY MEDICINE : CCLM / FESCC 2009 LNKD- PUBMED:19842993, vol. 47, no. 12, 21 October 2009 (2009-10-21), pages 1525 - 1530, XP008127121, ISSN: 1434-6621 *
MASSON-BESSIÈRE ET AL., CLIN EXP IMMUNOL, vol. 119, 2000, pages 544 - 552
MASSON-BESSIÈRE ET AL., J. IMMUNOL, vol. 166, 2001, pages 4177 - 4184
MOSCARELLO ET AL., J NEUROCHEM, vol. 81, 2002, pages 335 - 343
MOSCARELLO ET AL., MULT SCLER, vol. 8, 2002, pages 130138
NANDAKUMAR; HOLMDAHL, J IMMUNOL METHODS, vol. 304, 2005, pages 126 - 136
NARAYANAN K ET AL: "Long-term follow up of infliximab therapy in inflammatory arthritis", INDIAN JOURNAL OF RHEUMATOLOGY,, vol. 2, no. 1, 1 March 2007 (2007-03-01), pages 8 - 10, XP026951497, ISSN: 0973-3698, [retrieved on 20070301] *
NEELI INDIRA ET AL: "Histone deimination as a response to inflammatory stimuli in neutrophils.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 FEB 2008 LNKD- PUBMED:18209087, vol. 180, no. 3, 1 February 2008 (2008-02-01), pages 1895 - 1902, XP002587421, ISSN: 0022-1767 *
NIJENHUIS ET AL., CLIN. CHIM. ACTA, vol. 350, 2004, pages 17 - 34
O'CONNOR ET AL., ANN NEUROL, vol. 46, 1999, pages 470
PRITZKER ET AL., BIOCHEMISTRY, vol. 39, 2000, pages 5374 - 5381
PRITZKER ET AL., BIOCHIM BIOPHYS ACTA, vol. 1388, 1998, pages 154 - 160
R. S. COTRAN; V. KUMAR; S. L. ROBBINS: "Robbins Pathological Basis of Disease", 1989, W. B. SAUNDERS CO., pages: 75
RAATS ET AL., J REUMATOLOGY, vol. 30, 2003, pages 1696 - 711
RAATS JOS M H ET AL: "Recombinant human monoclonal autoantibodies specific for citrulline-containing peptides from phage display libraries derived from patients with rheumatoid arthritis", 1 August 2003, JOURNAL OF RHEUMATOLOGY, JOURNAL OF RHEUMATOLOGY PUBLISHING COMPANY, TORONTO, CA, PAGE(S) 1696 - 1711, ISSN: 0315-162X, XP008098343 *
RAATS, J.M.H.; WIJNEN, E.W; PRUIJN, G.J.M.; VAN DEN HOOGEN, F.H.M.; W.J. VAN VENROOIJ., J. RHEUM., vol. 30, 2003, pages 1696 - 1711
REPARON-SCHUIJT ET AL., ARTHRITIS RHEUM, vol. 44, 2001, pages 41 - 47
SEBBAG MIREILLE ET AL: "Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins.", EUROPEAN JOURNAL OF IMMUNOLOGY AUG 2006 LNKD- PUBMED:16838278, vol. 36, no. 8, August 2006 (2006-08-01), pages 2250 - 2263, XP002601412, ISSN: 0014-2980 *
SENSHU ET AL., ANAL BIOCHEM, vol. 203, 1992, pages 94 - 100
STEMMER ET AL., GENE, vol. 164, 1995, pages 49 - 53
VERPOORT K N ET AL: "Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles.", ARTHRITIS AND RHEUMATISM DEC 2007 LNKD- PUBMED:18050209, vol. 56, no. 12, December 2007 (2007-12-01), pages 3949 - 3952, XP002601413, ISSN: 0004-3591 *
VOSSENAAR ET AL., BIOESSAYS, vol. 25, 2003, pages 1106 - 1118
VOSSENAAR; VAN VENROOIJ, ARTHRITIS RES THER, vol. 6, 2004, pages 107 - 111
WOOD ET AL., ANN NEUROL, vol. 40, 1996, pages 18 - 24
WOOD ET AL., J BIOL CHEM, vol. 264, 1989, pages 5121 - 5127

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9109019B2 (en) 2009-12-10 2015-08-18 Modiquest B.V. Anti-inflammatory agents
USRE46990E1 (en) 2009-12-10 2018-08-14 Modiquest B.V. Anti-inflammatory agents
US10233236B2 (en) 2009-12-10 2019-03-19 Modiquest B.V. Method of treating or preventing rheumatoid arthritis
WO2013109185A1 (fr) * 2012-01-19 2013-07-25 Vilara Ab Nouveaux anticorps
WO2015116896A1 (fr) * 2014-01-31 2015-08-06 The General Hospital Corporation Traitement de la septicémie et du choc septique
US10131707B2 (en) 2014-01-31 2018-11-20 The General Hospital Corporation Treatment of sepsis and septic shock
AU2015359262B2 (en) * 2014-12-11 2021-02-04 Citryll B.V. Method for the treatment of idiopathic pulmonary fibrosis
WO2016092082A1 (fr) * 2014-12-11 2016-06-16 Modiquest B.V. Méthode de traitement de la fibrose pulmonaire idiopathique
CN107108725A (zh) * 2014-12-11 2017-08-29 莫蒂克斯特私人有限公司 特发性肺纤维化的治疗方法
US11066462B2 (en) 2014-12-11 2021-07-20 Citryll B.V. Method for the treatment of idiopathic pulmonary fibrosis
CN107108725B (zh) * 2014-12-11 2021-03-23 莫蒂克斯特私人有限公司 特发性肺纤维化的治疗方法
US10849965B2 (en) 2015-05-05 2020-12-01 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US11185577B2 (en) 2015-05-05 2021-11-30 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US11925679B2 (en) 2015-05-05 2024-03-12 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US11866512B2 (en) * 2017-11-22 2024-01-09 Vacara Ab Antibodies to citrullinated proteins
WO2020038963A1 (fr) 2018-08-21 2020-02-27 Modiquest B.V. Anticorps se liant à l'histone citrullinée 2a et/ou 4
US11345750B2 (en) 2018-08-21 2022-05-31 Citryll B.V. Antibodies binding to citrullinated histone 2A and/or 4
EP4085973A1 (fr) 2021-05-04 2022-11-09 Citryll B.V. Inhibition de pièges extracellulaires éosinophiles
WO2022233931A1 (fr) 2021-05-04 2022-11-10 Citryll B.V. Inhibition de la formation de pièges à éosinophiles

Also Published As

Publication number Publication date
US20150307603A1 (en) 2015-10-29
US9109019B2 (en) 2015-08-18
JP5980683B2 (ja) 2016-08-31
EP3095794A1 (fr) 2016-11-23
US10233236B2 (en) 2019-03-19
EP2509999B1 (fr) 2016-05-11
USRE46990E1 (en) 2018-08-14
EP2509999A1 (fr) 2012-10-17
KR20120120492A (ko) 2012-11-01
AU2010329842A1 (en) 2012-06-28
CA2783691A1 (fr) 2011-06-16
US20210087260A1 (en) 2021-03-25
CA3027786A1 (fr) 2011-06-16
CA2783691C (fr) 2019-05-07
KR101786136B1 (ko) 2017-10-17
US20120321631A1 (en) 2012-12-20
US20190119368A1 (en) 2019-04-25
EP2332987A1 (fr) 2011-06-15
JP2013513374A (ja) 2013-04-22
AU2010329842B2 (en) 2014-03-06
ES2587083T3 (es) 2016-10-20

Similar Documents

Publication Publication Date Title
US10703822B2 (en) Anti-inflammatory agents
US20210087260A1 (en) Method of Treating or Preventing Rheumatoid Arthritis
US11345750B2 (en) Antibodies binding to citrullinated histone 2A and/or 4
AU2015359262A1 (en) Method for the treatment of idiopathic pulmonary fibrosis
Chirivi et al. Anti-citrullinated protein antibodies as novel therapeutic drugs in rheumatoid arthritis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10788080

Country of ref document: EP

Kind code of ref document: A1

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10788080

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010788080

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010329842

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2783691

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012542572

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2010329842

Country of ref document: AU

Date of ref document: 20101210

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20127017692

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13514923

Country of ref document: US